Pneumococcal disease

Biology

Community-acquired pneumonia

Pneumococcal pneumonia

Immunology

Pediatrics

Streptococcus pneumoniae

Physics

Optics

Vaccination

Antibiotics

Microbiology

Internal medicine

Medicine

Serotype

Pneumonia

Pneumococcal infections

Pneumococcal polysaccharide vaccine

Incidence (geometry)

Respiratory Medicine

BackgroundThe burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined.MethodsStructured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe.ResultsThe overall incidence rates for CAP was 68–7000 per 100,000 and the incidence in hospitalised CAP cases of all causes was 16–3581 per 100,000. In general the incidence of CAP increased consistently with age. Available data indicated higher burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases of pneumococcal CAP (30%–78%) were caused by serotypes covered by PCV13 vaccine; the incidence of PCV13-related pneumonia decreased after the introduction of childhood vaccination.ConclusionsWe observed a high burden adult pneumococcal CAP in Europe despite use of the 23-valent pneumococcal polysaccharide vaccine, particularly in elderly patients with comorbidities. CAP surveillance presented wide variations across Europe. Pneumococcal CAP has to be monitored very carefully due to the possible effect of current vaccination strategies.

Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review